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Abstract: Superparamagnetic magnetite nanoparticles (MNPs) with excellent biocompatibility and
negligible toxicity were prepared by solvothermal method and stabilized by widely used and
biocompatible polymer poly(ethylene glycol) PEG-4000 Da. The unique properties of the synthesized
MNPs enable them to host the unstable and water-insoluble quercetin as well as deliver and localize
quercetin directly to the desired site. The chemical and physical properties were validated by X-ray
powder diffraction (XRPD), field emission scanning electron microscopy (FE–SEM), atomic force
microscopy (AFM), superconducting quantum interference device (SQUID) magnetometer, FTIR
spectroscopy and dynamic light scattering (DLS). The kinetics of in vitro quercetin release from
MNPs followed by UV/VIS spectroscopy was controlled by employing combined stationary and
alternating magnetic fields. The obtained results have shown an increased response of quercetin
from superparamagnetic MNPs under a lower stationary magnetic field and s higher frequency of
alternating magnetic field. The achieved findings suggested that we designed promising targeted
quercetin delivery with fine-tuning drug release from magnetic MNPs.
Keywords: release kinetics; superparamagnetism; stationary magnetic field; alternating magnetic
fields; magnetic nanoparticles; quercetin
1. Introduction
Quercetin (C15H10O7, 3,3′,4′,5,7-pentahydroxyflavone) is a major member of the
flavonols, a subclass of flavonoids, natural polyphenols [1]. It is an important compo-
nent of the human’s daily diet and widely distributed in vegetables and fruits such as
onions, tomatoes, berries, grapes, nuts, as well as in many flowers and leaves [2,3]. In
addition, quercetin exhibits a wide range of biological and pharmacological activities,
including antioxidant, anti-inflammatory, antibacterial, anti-anaemic, and anticarcinogenic
activities [1,3–5]. Extensive studies have reported that quercetin can inhibit the prolifera-
tion of several types of cancers such as lung, prostate, breast cancer, and pancreatic tumour
cells [1]. In addition, the main feature of quercetin is its antioxidant potential of OH groups
in the structure that can bind to reactive oxygen species (ROS) and maintain cell viability.
Quercetin has been shown to decrease the activity of antioxidant and apoptotic proteins
and increase the levels of antiapoptotic proteins [6]. However, its therapeutic and clinical
properties are limited due to its hydrophobic nature and low stability in the physiological
medium. The problem with instability, low solubility and poor bioavailability can be
successfully overcome by their loading in drug delivery systems including nanoparticles
(NPs) [3,5,7,8]. The rapid growth of nanotechnology is the key to a revolutionary platform
for chemical, physical, biological and mechanical properties of various materials [9,10].
There is tremendous interest in nanomaterials or NPs in the biomedical field [11]. For
example, a variety of NPs is envisioned to be used in medical applications such as cancer
detection, magnetic resonance imaging, cardiovascular and neurological treatment diseases,
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targeted drug delivery, hyperthermia, bioseparation, and gene transfer [3,9,10]. In recent
years, magnetic nanoparticles (MNPs) have been highlighted among the many types of
NPs [12–14]. Essentially, researchers were attracted by their excellent unique physical,
chemical and magnetic properties [15]. In 1957, Gilchrist and coworkers showed the first
use of magnetic particles for inductive heating of lymph nodes in dogs [16,17].
In 1983, Widder and coworkers reported the first use of MNPs containing doxoru-
bicin to treat Yoshida rat sarcoma with an external magnetic field. These results repre-
sented a compelling advance in chemotherapy treatment, with complete cancer remission
demonstrated in 77% of animals in the magnetically localized doxorubicin-magnetite mi-
croparticles [17,18]. MNPs have received much attention as target drugs that can replace
traditional chemotherapy without the side effects [19]. Several inorganic magnetic nanopar-
ticles (MNPs) have the potential to be used for drug delivery, but MNPs are the only
magnetic materials approved by the Food and Drug Administration (FDA) for human
use [3,19–21]. Numerous physical, biological and chemical preparation methods have
been accepted for the MNP’s synthesis [22]. Magnetite NPs are most commonly used in
biological applications due to their unique physicochemical properties such as particle size,
size distribution, shape and high surface area [23,24]. They exhibit interesting properties
such as superparamagnetism, high field irreversibility and high saturation field [24–26].
Due to these properties, the superparamagnetic NPs can become magnetized when the
external magnetic field is used and they do not remain magnetized when the field is turned
off. The localization of drugs with MNPs in combination with an external magnetic field
and their retention until the completion of therapy [26] represent a promising strategy
of drug delivery with the controlled release [27]. The effectiveness of magnetic delivery
systems includes the field strength, gradient, magnetic and physicochemical properties
of the NPs [28]. Moreover, the main challenge of bare MNPs is to avoid their agglom-
eration due to their van der Waals and magnetic dipole–dipole attraction forces [13,29].
Considering their hydrophobic surface and rapid clearance from the blood through the
reticuloendothelial system (RES), they are not suitable for drug delivery systems [22].
Therefore, to overcome this inconvenience, it was necessary to coat the magnetite NPs
to reduce the aggregation tendency, protect their surface from oxidation, and make the
particles biocompatible and stable [30].
Various polymers have been used for drug delivery, with polyethylene glycol (PEG)
being the gold standard and the most commonly used polymer [31]. PEG is approved by
the Food and Drug Administration (FDA) for internal use in humans and its products have
been on the market for 20 years [23,31]. Since 1994, Gref and co-workers have reported on
the PEG coating and demonstrated that the naked particles were removed from the liver
only 5 min after injection [31]. PEG coating is extensively used in the preparation of NPs
for biomedical applications due to its many advantages, such as stability in physiological
media, prolonged half-life in the body, biocompatibility, and water solubility. Moreover,
PEG coating prevents or reduces aggregation and confers better physical stability to drugs
through steric and hydric repulsion [19,31].
In this study, we synthesized MNPs, which are known to have excellent biocompati-
bility and negligible toxicity [26], allowing their application in therapy. Prepared by the
solvothermal method and stabilized by the widely used PEG, MNPs possess unique prop-
erties, such as colloidal stability, dispersibility, high porosity, high loading capacity, and
specific morphological, thermal, and magnetic properties, especially superparamagnetism,
which enable them to host the unstable or water-insoluble drugs and to direct and localize
the drugs to the specific site in the tissue. The synthesized MNPs were fully characterized
in terms of structural, morphological and magnetic properties. In addition, the kinetics
of quercetin from the MNPs were controlled in vitro by simply varying stationary and
alternating magnetic fields, resulting in fine-tuned manipulation of the released quercetin
as a model drug. It should be noted that in this study cytotoxicity has been considered, but
it was not a priority at this stage of our research. Regarding the measurement and result in
the cytotoxicity literature of MNPs, we quite rightly expected at least the same cytotoxicity
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as the results obtained by Barreto et al. [3], Hua et al. [32] and Luo et al. [33]. It was shown
that the system developed provides prolonged quercetin release, which is an important
characteristic of targeted drug delivery systems. The enhanced quercetin release at the
lower stationary magnetic field and higher frequency alternating magnetic field, together
with the synergism of chemical and physical, i.e., superparamagnetic properties of MNPs,
demonstrate the great potential of MNPs as a promising targeted drug delivery system
with high potential for their, both therapeutic and diagnostic activity
2. Materials and Methods
2.1. Chemicals
Iron (III) chloride hexahydrate (97%) was purchased from Alfa Easar (Ottawa, ON,
Canada). Ammonium acetate and polyethylene glycol (PEG, Mw = 4000 Da) were obtained
from Sigma Aldrich (St. Louis, MO, USA). Ethylene glycol and ethanol (96%) were pur-
chased from Lach-ner (Neratovice, Czech Republic). Compressed nitrogen was purchased
from Messer (Bad Soden am Taunos, Germany). Silicon oil was received from Acros or-
ganics (Waltham, MA, USA). Phosphate buffered saline (PBS) buffer (PBS tablets, pH 7.4,
Ic = 150 × 10−3 mol dm−3) were purchased from Sigma Aldrich (St. Louis, MO, USA).
Deionized water Millipore mili Q-H2O was used to prepare the PBS medium. Quercetin
(≥99%) was supplied by Lach-ner (Neratovice, Czech Republic). A molecular weight
cut-off dialysis bag (MWCO, 8Kd) was purchased from Thermo Fisher Scientific (Waltham,
MA, USA).
2.2. Synthesis of Bare and PEG Coated Magnetite MNPs
The modified solvothermal reaction was used for the preparation of mesoporous
magnetic nanoparticles [33,34]. Briefly, 1.35 g FeCl3 × 6H2O, 3.85 g of CH3COONH4, 1.0 g
PEG (M = 4 kD) and 70 mL of ethylene glycol were added to a 250 mL two-necked flask
equipped with a magnetic rod. The mixture was stirred vigorously for 1 h at 160 ◦C with
a Heidolph MR Hei-Standard mixer (Schwabach, Germany). The chemical reaction was
under the protection of an inert nitrogen atmosphere to form a homogeneous brownish
solution (see Figure 1). After an hour, the system was stopped and cooled to room tem-
perature. The mixture was transferred into a Teflon-coated stainless-steel autoclave (BHL
800 Berghof, Eningen, Germany) which is connected to a temperature controller. The
autoclave was heated to 200 ◦C and maintained for 19 h and, afterwards, it was cooled to
50 ◦C. To remove the solvent, MNPs were centrifugated (Universal 320 Hettich Zentrifu-
gen, Tuttlingen, Germany) at 8000 rpm for 10 min. After separation, MNPs were washed
several times with ethanol and dispersed with a shaker (IKA Shaker Vortex 1, Staufen,
Germany) between each wash. Finally, MNPs were left to dry in a desiccator for further
characterization. For comparison purpose and characterization of NPs, bare magnetite
MNPs were resynthesized each time using the same procedure.
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2.3. Characterization of Synthesized Magnetite MNPs
The structural characteristics were determined by X-ray powder diffraction using
Philips MPD 1880 diffractometer (Brooklyn, NY, USA) with monochromatic CuKα radiation
(λ = 0.154 nm) at room temperature. The structural features of prepared samples were
recorded at 2θ angles in the range of 10◦–70◦ with a step of 0.02◦ and fixed time of 10 s per
step. X-ray diffraction in polycrystalline is used to confirm crystalline size and structure
of bare and coated magnetite MNPs obtained by solvothermal method. Field emission
scanning electron microscope, JEOL JSM-7000F (Tokyo, Japan), was used to determine
the morphology, particle size distribution and surface texture of bare and PEG-coated
magnetite MNPs. FE-SEM was linked to the EDS/INCA 350 (energy dispersive X-ray
analyzer) manufactured by Oxford Instruments Ltd., London, UK. The morphology of the
MNPs has been further investigated using atomic force microscopy (AFM). The samples
for AFM imaging were prepared by deposition of a magnetite MNPs suspension on the
mica substrate. The MNPs are rinsed three times with 50 µL of MiliQ water to remove
all residual impurities. AFM images were obtained by scanning the magnetite MNPs on
the mica surface in the air using MultiMode Scanning Probe Microscope with Nanoscope
IIIa controller (Bruker, Billerica, MA, USA) with SJV-JV-130 V (“J” scanner with vertical
engagement); Vertical engagement (JV) 125 µm scanner (Bruker Instruments, Inc., Bruker,
Billerica, MA, USA). Tapping mode was performed for imaging using silicon tip (R-TESPA,
Bruker, Nom. Freq. 300 kHz, Nom. spring constant of 40 N/m) at 25.0 ◦C, allowing
thermal equilibration before each imaging. AFM images were collected using random
spot surface sampling (at least two areas per sample) for each analysed sample. All the
images were processed by first-order flattening only and analysed using the NanoScope
Analysis software (Version 5.31r1). Morphology analysis was investigated by Transmission
Electron Microscope (TEM), Zeiss EM10 (Oberkochen, Germany), operated at 100 kV. In
this propose, MNPs coated with PEG were dispersed in Milli-Q H2O and bare MNPs were
dispersed in ethanol, ultrasonicated and placed on carbon coated copper grids. After air
drying, samples were photographed by transmission electron microscopy. Samples were
analysed with ImageJ and 50 particles were counted for each image.
The MNPs mesoporosity determination has been performed using nitrogen
adsorption–desorption measurements on an ASAP2020 (Micromeritics, Norcross, GA,
USA) accelerated surface area analyzer at 77 K. Before measuring, the samples were de-
gassed at reduced pressure andat 120 ◦C for at least 6 h. All measurements have been made
in duplicate. The specific surface area, the pore volume and the pore size are determined
using Brunauer–Emmett–Teller (BET) analysis. To confirm the superparamagnetic property
of the synthesized MNPs, magnetization measurements were performed. Magnetization
of the powder samples of MNPs was measured using a commercial Quantum Design
MPMS-5 SQUID magnetometer (San Diego, CA, USA). The powder samples were placed
into a small ampoule whose diamagnetic contribution was properly subtracted. In addition,
the field dependence of the magnetization (M(H)), including magnetic hysteresis loops,
was measured at 300 K under fields up to 10 kOe.
2.4. The Determination of Loaded Quercetin into Magnetic Mesoporous MNPs
The quercetin loading efficiency into mesoporous MNPs has been confirmed using
Brunauer–Emmett–Teller (BET) analysis. The difference in the specific surface area, the pore
volume and the pore size before and after immersing the MNPs into the quercetin solution
confirmed the loading of quercetin into MNPs. FTIR spectra were obtained by Alpha-T
FTIR Spectrometer (Bruker, Billerica, MA, USA). All spectra were recorded between 4000
and 350 cm−1 at a nominal resolution of 4 cm−1 at 25 ◦C, and the total number of recordings
was 16. Dried samples were mixed with KBr powder and then they were pressed to produce
pellets. TG analysis data were carried out on a TG/DTA simultaneous analyser DTG-60H
with a 10 ◦C/min heating rate under a nitrogen atmosphere. The measurements were
recorded in a range of room temperature up to 1200 ◦C.
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UV/VIS spectrophotometer was used to study the quercetin loading efficiency of the
synthesized MNPs. The loading efficiency was calculated by measuring the absorbance of
the supernatant with the WTW photoLab® 7600 UV-VIS Spectrophotometer (Xylem, Rye
Brook, NY, USA) at 374 nm. Measurements were performed in a rectangular quartz cuvette
with a 10 mm optical path length and covers at 25 ◦C.
A total of 500 mg of quercetin was dissolved in 100 mL of ethanol and suspended in
an ultrasonic bath (Bandelin Sonorex Super RK 100 H, Berlin, Germany) for 1 h at room
temperature. The 25 mL aliquot of quercetin solution and 100 mg of coated MNPs were
transferred into a 50 mL Falcon conical centrifuge tube. The mixture was mechanically
stirred at a thermocontrol shaker (Barnstead Lab-line 4450 e-class) for 24 h at 200 rpm and
25 ◦C. Afterwards, the quercetin-loaded MNPs were separated from unloaded quercetin by
centrifugation (Universal 320 Hettich Zentrifugen, Tuttlingen, Germany) at 8000 rpm for
15 min. Compared with quercetin concentration supernatant before adding the synthesized
MNPs, the concentration loss was determined using a calibration curve in pure EtOH. The
coefficient of determination was 0.9978, and the determined molar absorption coefficient
of quercetin at temperature 298 K and 374 nm is 19,131 mol−1 cm−1 dm3. The loading
efficiency (LE) was calculated by measuring the absorbance of the supernatant with the
Photolab 7600 UV-VIS spectrophotometer (Xylem, New York, NY, USA) at λ = 374 nm.
The absorbance (λ = 374 nm) was collected and converted to concentration by using the
equation from the calibration curve. Therefore, the drug loading efficiency was calculated





where membedded represent the mass of quercetin incorporated in nanoparticles, and mNP is
the total mass of MNPs which is used for loading.
Size Distribution of Magnetic MNPs Using Dynamic and Electrophoretic Light Scattering
Hydrodynamic diameter (dH) and zeta potential (ζ) of suspended MNPs were mea-
sured by photon correlation spectrophotometer, Zetasizer Nano ZS (Malvern, UK) with
green laser (λ = 532 nm) using the M3-PALS technique. All measurements were conducted
at 25 ◦C in PBS (pH = 7.4) buffer. The hydrodynamic diameter was determined from the
peak maximum of the volume size function. The zeta potential (ζ) was calculated from the
electrophoretic mobility using a Smoluchowski approximation (f (κa) = 1.5). The dH values
were obtained as an average value of 10 measurements, while the zeta potential values
were reported as an average of 3 independent measurements. The results were collected by
the Zetasizer software 6.32 (Malvern Instruments, Malvern, UK).
2.5. Release Study of Quercetin under Stationary and Alternating Magnetic Fields
The apparatus setup scheme shown in Figure 2 enables the fine-tuning of the quercetin-
release kinetic profile under applied combined stationary and alternating magnetic fields.
The magnetic field enforced in the experiment is a combination of stationary and alternating
magnetic fields. The position of the permanent magnet fixed and stable towards the fixed
magnetic coil placed within the reactor ensures the permanent and alternating magnetic
fields perpendicular to each other [35]. Without going into more detail, we showed in
previous work [35] that, by applying external magnetic fields, MNPs behave as Brownian
particles with quasi-periodic movement that enables loaded drug molecules to became
enhanced released from the MNPs. A magnetic field is an effective stimulus with deep
penetration capacity. The high-frequency alternating magnetic field (HF-AMF), from 50 to
400 kHz, and low-frequency alternating magnetic field (LF-AMF), from 0.1 to 5 kHz, have
been employed to trigger the release of drugs from nanocarriers [36]. In our previous work,
we employed the LF-AMF to induce the flavonoid release from the magnetic aggregates [35].
To get more insights into the effect of the combination of applied permanent and AMF to
drug release, we designed sophisticated HF-AMF instrument to induce increased drug
release at HF-AMF having in mind Brezovitch criterion [37]. He proposed a safety limit
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where the product of magnetic field and amplitude frequency (H0×f) should not exceed
4.85 × 108 A m−1 s−1 to avoid any harmful effect on the organism. In our study, the
product amounts 4 mA m−1 s−1, 1 mA m−1 s−1 and 0.3 mA m−1 for 100 kHz, 50 kHz
and 10 kHz, respectively, indicating that we chose good frequencies and applied magnetic
fields for any possible safe application to patients. In consideration of the design of our
experiment, where there were relatively high frequencies of alternating magnetic fields
(from 10 to 100 kHz), it was expected that the release of quercetin would be significantly
enhanced by the influence of higher frequency.
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and 37 °C) in the mixture PBS/EtOH (vol. 50/50) in which the solubility of quercetin totals 
to 5.66 mg/mL, 5.83 mg/mL and 6.02 mg/mL at 25 °C, 30 °C and 37 °C, respectively [38]. 
For the use of NPs as a drug delivery system, a physiological temperature of 37 ° C is of 
crucial importance. However, before the application of MNPs, they must be adequately 
stored. There are studies on the storage of MNPs at low temperatures, and the influence 
of low temperatures on the magnetic properties of MNPs [39]. Although the temperature 
effects on the magnetic properties of magnetite are very weak, MNPs contain a coating of 
organic material, in our case PEG 4000. Since PEG 4000 has crystallization temperatures 
i r . eri e t l set f t e rele se i etics sc e atic ill stration of a reactor.
r g release was calculated by measuring the absorbance of quercetin releas d in
the supernatant at λ = 330 nm by the UV- is spectrophotometer. The releasing kinetics of
querc tin from magnetit MNPs was investigated at three temp ratures (25 ◦C, 30 ◦C and
37 ◦C) in the mixture PBS/EtOH (vol. 50/ ) in whic t e solubility of querc tin totals to
5.66 mg/mL, 5.83 mg/mL and 6.02 mg/ L at 25 ◦ , 30 ◦ a 37 ◦ , res ecti el [38].
For the se of s as a r g delivery syste , a physiological te erat re of 37 ◦ is of
crucial i portance. o ever, before the application of Ps, they ust be adequately
stored. There are studies on the storage of Ps at lo te peratures, and the influence
of low te peratures on the agnetic properties of NPs [39]. Although the te perature
effects on the magnetic properties of magnetite are very weak, NPs contain a coating of
organic material, in our case PEG 4000. Since PEG 4000 has crystallization temperatures at
around 32 ◦C [40], which means that by changing the temperature of the MNPs suspension
from the storage temperature to the ambient temperature, and further to the physiological
temperature of 37 ◦C, the surface properties of MNPs and the relaxation kinetics could be
changed. For this reason, measurements were made not just at 37 ◦C, but also at 25 and
30 ◦C to see how much the temperature change affects the drug-release kinetics. In addition,
similar studies of the mechanism of release kinetics from NPs at different temperatures
(10, 22 and 37 ◦C) have been conducted, for example, in study by Gronczewska [41], in
that drug release and matrix degradation of polymer microspheres with different glass
transition temperatures were investigated at various temperatures in order to clarify the
effect of temperature on mechanisms of drug release. Then, 100 mg of quercetin-loaded
MNPs were transferred in a dialysis bag (MWCO 8 kD, Thermo Fisher Scientific (Waltham,
MA, USA)), after which 1 mL of PBS/EtOH (Vol. % = 50:50) medium was added and closed
with dialysis bag clip holders. The dialysis bag was placed in a glass cylindrical reactor
with a thermostatic jacket and flange size LF 100 containing 150 mL of PBS/EtOH mixture.
The overhead stirrer (Ministar 20 control, IKA-Werke GmbH&Co (Staufen, Germany)) is
going through the centre neck flat flange lid. The stirrer was set to 200 rpm. At selected
time intervals, 1 mL of supernatant was replaced with fresh PBS/EtOH mixture through
one angled side neck flat flange lid. The reactor is connected to a refrigerated–heating
circulator (Corio CD-201F Julabo GmbH (Seelbach, Germany)) to control the appropriate
temperature. The controlled release of quercetin was tested using appropriate external
alternating (10 kHz, 50 kHz and 100 kHz) and stationary magnetic fields (B = 7.9 mT
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and 11.0 mT) at controlled electric current (I = 100 mA). An external alternating magnetic
field was achieved with a function generator (Wavetek 164 30 MhZ (San Diego, CA, USA)
connected to the coil (N = 270, l = 4 cm). Experiments were performed using the magnetic
field system set up from permanent disk-shaped magnets (rare earth) and solenoid with
permalloy core connected to signal generator alternating 100 mA current. A reactor with
the sample was placed among the two magnetic fields. Defining the Oxy plane as the
surface of the liquid, the permanent field was along the Oz axis and the alternating field
along the Ox axis. Weak fields were applied in all experiments: the strength of the static
permanent magnetic fields at the appropriate distance between the membrane dialysis bag
and the permanent magnet was B = 7.9 mT and 11.0 mT. They were placed on a stand inside
the reactor and used as sources of the permanent magnetic field. The function generator is
connected to the oscilloscope (DS1000Z, Rigol Technologies (Beijing, China), which allowed
the observation of the sinus waveform signal. The release kinetics of quercetin from
magnetite MNPs was quantified by UV/VIS spectrophotometry (Photolab 7600 UV/VIS
spectrophotometer Xylem (New York, NY, USA)). The linearity of the calibration was found
to be valid from 1 × 10−6 mol dm−3 to 1 × 10 −4 mol dm−3 with correlation coefficients
for quercetin all approaching 1.00. All release kinetics experiments have been performed
in duplicate.
3. Results and Discussion
3.1. Characterization of Synthesized Magnetite MNPs
The X-ray powder diffraction patterns of the synthesized bare and PEG-coated MNPs
are presented in Figure 3A,B, respectively. Characteristic peaks exhibited in the XRPD
pattern are well-matched with the magnetite diffraction peaks and confirm the cubic
inverse spinel structure of MNPs. The sharp diffraction of three characteristic peaks (220),
(311) and (400) also indicate the spinel structure of magnetite [42]. The formation of pure
cubic magnetite is confirmed by the value of the calculated lattice parameter “a” which
has been determined to be 8.389 Å [43]. Using Scherrer’s equation, the average crystallite
size of bare and PEG-coated MNPs were calculated to be 25 nm and 19 nm, respectively. In
addition, the decreased average crystallite size, another piece of evidence suggesting that
PEG decreases the crystallinity of MNPs at a lower intensity and with broader diffraction
peaks than PEG-coated MNPs.
The size and morphology of bare and PEG-coated mesoporous MNPs were observed
by field-emission scanning electron microscope (FE-SEM), atomic force microscopy (AFM)
and transmission electron microscopy (TEM), as shown in Figure 3A,B,G–J,K–L). Both bare
and PEG-coated MNPs maintain a uniform spherical shape, some of them agglomerated
due to magneto–dipole interactions between MNPs. While bare MNPs showed cluster
structure with a very rough surface, the process of PEG coating revealed the flattened
surface of mesoporous MNPs (Figure 3I,J). These findings have been confirmed by AFM
imaging where the roughness of the MNPs surface has been increased by PEG coating, for
almost 100%, from 5.58 ± 1.06 nm to 10.9 ± 2.1 nm, confirming the effective coverage of
the bare MNPs by PEG [43]. The less agglomerated texture of the PEG-coated MNPs can
be related to the effect of the PEG layer during the synthesis of MNPs. In addition, a size
histogram of bare mesoporous MNPs obtained using SEM micrographs shows a broader
size distribution than PEG-coated MNPs (dave = 103.4 ± 0.7 nm and 101.0 ± 0.9 nm for
bare and PEG-coated MNPs, respectively), indicating that polymer decreased the magnetic
interaction among the particles and prevent their agglomeration. The cluster structure
of mesoporous MNPs has been confirmed using AFM. The average size of bare MNPs
and PEG-coated MNPs corresponds to results obtained by SEM, it was even 10% larger
due to the convolution effect. However, in both 2D height images, it is shown that the
cluster structure MNPs consists of smaller substructures, in the range of 15 to 35 nm, which
roughly correspond to the dimension of the crystallite size obtained by X-ray powder
diffraction. Hence, AFM revealed that only several nanometers increase in roughness is
observed when PEG 4 kD is used, suggesting that the PEG layer is largely twisted the
Antioxidants 2021, 10, 1212 8 of 20
magnetite surface, rather than stretch out linearly [44]. Furthermore, this PEG layer should
decrease the magnetic interactions among the MNPs and prevents their agglomeration.
The mean diameter of bare MNPs obtained by TEM is larger (143 ± 30 nm) than obtained
by SEM (103.4 ± 0.7 nm), indicating a higher degree of polydispersity. However, the mean
diameter of PEG-coated MNPs (96 ± 10 nm) corresponds the value obtained by SEM
(101.0 ± 0.9 nm). Increasing the size of the PEG-coated MNPs can be attributed to the
successful coating of PEG. As shown in Figure 3K,L, both MNPs maintain a typical spheri-
cal shape.
Nitrogen adsorption–desorption isotherms of bare MNPs confirmed their mesoporos-
ity (see Figure 4). The surface area, pore size and total pore volume were calculated to
be 20.5 m2g−1, 17.7 nm and 0. 09 cm3 g−1, respectively, strongly supporting the fact that
the bare MNPs have mesoporous structure. The PEG coating of bare MNPs led to a slight
decrease in surface area (19.3 m2 g−1) but an increase in pore size and total pore volume
(24.6 nm1 and 0.11 cm3 g−1, respectively).
FTIR spectrum (Figure 5A) of bare magnetite MNPs shows bands at 585 and 395 cm−1
corresponding to the symmetric stretching vibration mode of the Fe-O bond. The absorp-
tion maxima at 3452 cm−1 and 1644 cm−1 suggest the presence of O-H linkages. In the pure
PEG, the bands at 1341 and 1100 cm−1 belong to the C-O-C ether bond asymmetric and
symmetric stretching vibrations. The band at 2890 cm−1 is attributed to -CH2- stretching
vibration in PEG. In addition, absorption bands at 1283 and 1465 cm−1 attributed to the
vibration of–CH2 and at 964 cm−1 corresponds to the CH out-of-plane vibration [18]. The
hydroxyl groups were also confirmed at 3444 and 1631 cm−1. The presence of characteristic
FTIR bands of PEG in PEG-coated MNPs spectrum confirmed the successful coating of
PEG on the surface of magnetite MNPs. The PEG-coated MNPs spectrum shows a strong
C-O-C ether stretch at 1110 and 1381 cm−1 [44]. In addition, the O-H linkages at the
1642 and 3445 cm−1 bands exhibited enhanced intensity which also indicates that PEG
modified the surface of MNPs. The transmittance bands at 589 and 399 cm−1 confirm the
symmetric stretching mode of the Fe-O bond. The results indicate that PEG is successfully
functionalizing the surface of MNPs.
In order to confirm the superparamagnetic properties of synthesized bare and PEG-
coated MNPs, measurements of the magnetization curve have been performed. The
S-shaped hysteresis loops are a typical feature of superparamagnetic MNPs and obtained
result is very similar to our previous work (77 emu g−1) on Fe3O4 MNPs [35]. The
magnetization curve clearly shows that magnetization depends on the applied magnetic
field, but not on the sign of the applied field. Magnetic characterization at 300 K indicates
that the bare MNPs have saturation magnetization at the maximum field of 5 kOe value of
76.71 emu g−1, which is lower than obtained value for the bulk Fe3O4 (Ms = 92 emu g−1) [42]
or Ms = 96.43 emu g−1 [19].
The observed decrease in the saturation magnetization could be explained either
by the use of PEG for the surface modification process [43] that causes the softening of
the magnetization or by the difference in particle size [45]. In addition, the saturation
magnetization of PEG-coated MNPs at the maximum field of 5 kOe is 74.75 emu g−1,
somewhat lower than bare MNPs (Figure 5B). However, the magnetization measurement
of synthesized MNPs confirmed their superparamagnetic properties, thus confirming their
further application in release studies under applied magnetic fields.
3.2. Loading of Flavonoid into Magnetite MNPs
The FTIR spectrum (Figure 6A,B) of quercetin detected OH group stretching at
3403 cm−1 and 3328 cm−1. The band at 1664 cm−1 corresponds to the C = O aryl ke-
tonic stretching and the bands at 1617 cm−1, 1558 cm−1 and 1520 cm−1 correspond to
C = C aromatic ring stretching. OH bending of the phenol functional group at 1375 cm−1
and 1314 cm−1 belongs to the in-plane bending of C–H in aromatic hydrocarbon. Bands
at 933 cm−1, 820 cm−1, 639 cm−1 and 602 cm−1 correspond to aromatic C–H out-of-plane
bendings. The C–O stretching in the aryl ether ring and the C–O stretching in phenol
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corresponds to 1244 cm−1 and 1210 cm−1 transmittance maxima. The band at 1167 cm−1 is
attributed to the C–CO–C stretch and bending mode in ketone, respectively. The FTIR spec-
tra of quercetin-loaded MNPs show the broadening of the OH band at 3446 cm−1, which
confirms the entrapment of quercetin in MNPs [46]. The interval from 1560 to 816 cm−1
matches very well with pure quercetin peaks and indicates successful loading [46].
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Figure 3. XRD pattern of (A) mesoporous bare MNPs Fe3O4; (B) PEG-coated MNPs; SEM images
of (C) bare Fe3O4 MNPs showing the rough rounded cluster with extensive open porosity ranging
from 30 to 200 nm in diameter; (D) SEM image of the surface of PEG-coated Fe3O4 MNPs ranging in
di-ameter from 50–130 nm; Histogram of bare MNPs Fe3O4 (E) and PEG-coated Fe3O4 MNPs (F);
(2D height topographic AFM image of single (E) bare magnetite Fe3O4 MNPs (G) and (F) PEG-coated
Fe3O4 MNPs (H) showing cluster structure details; 2D-amplitude AFM image of single (G) bare
magnetit (I) and (H) PEG-coated MNPs (J) showing subcluster structures in size range from 10
to 30 nm; TEM images of ( ) are i age of the surface of PEG-coated
Fe3O4 MNPs.
The loading of quercetin has been also confirmed using nitrogen adsorption–desorption
isotherms of quercetin-loaded PEG MNPs. In comparison to PEG covered MNPs, the
surface area has been decreased by almost 19% to 15.7 m2 g−1, pore size decreased to
14.2 nm for 42.4%, while total pore volume amounting 0.06 cm3 g−1, decreased for 49% to
0.06 cm3 g−1, strongly supporting the fact that the quercetin has been effectively loaded
into MNPs.
The thermogravimetric study was performed to confirm the quercetin loading in
MNPs. Figure 6C shows comparative weight loss for quercetin and quercetin-loaded
MNPs. A thermogravimetric study of quercetin reveals that the compound undergoes
a three-stage thermal decomposition. The first stage of mass loss begins at 30 ◦C and
continues up to 133 ◦C. A mass loss of 3.52% is attributed to dehydration or loss of water
molecules on the surface of quercetin. In the temperature range 133 ◦C to 385 ◦C, the
compound experiences a weight loss of 28.5% due to the melting of quercetin. The final
thermal decomposition is observed in the temperature range of 385 ◦C to 1110 ◦C, and
the weight loss of quercetin is 67% [47]. In the case of quercetin-loaded MNPs, the weight
loss in the temperature range from 30 ◦C to 1200 ◦C is about 12.2%, which is attributed
to the decomposition of organic compounds from MNPs. This data results in the great
thermal stability of quercetin when it has been encapsulated in MNPs. In the case of
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PEG-coated MNPs, there is an increase in the weight gain resulting from the burning of
the PEG and oxygenation of Fe3O4 starting at 270 ◦C under the continuous flow of oxygen
at high temperatures and finishing at 450 ◦C [48]. However, the weight loss of PEG from
the PEG-coated MNPs amounts to 4%. It is assumed that the thermal decomposition of
PEG occurs at both C-O and C-C bonds of the backbone chain [49]. The influence of the
quercetin loading into magnetite MNPs on the size and morphology of the MNPs has
been further investigated. 2D height AFM image (Figure 6D) and 2D-amplitude AFM
image (Figure 6E) revealed that distinct subcluster structure containing MNPs has been
retained irrespective of quercetin loading, with size grains from 20 to 50 nm in diameter.
The roughness value after quercetin loading decreased from (10.9 ± 2.1) nm to (4.86 ± 1.1)
nm additionally confirming the successful loading of quercetin to PEG loaded MNPs.
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In addition, UV/VIS spectroscopy is used to study quercetin loading efficiency. Com-
pared with quercetin concentration before adding the synthesized MNPs, the concentration
loss was determined using a calibration curve in pure ethanol (EtOH). The coefficient of
determination was 0.9978, and the determined molar absorption coefficient of quercetin at
298 K and 374 nm is 19,131 mol−1 dm3 cm−1. The loading efficiency (LE) was determined
to be (20.2 ± 1.3%) calculated from 17 independent experiments. Our results suggest
significant improvement of the loading efficiency of the quercetin compared with a loading
efficiency of solid lipid NPs (13.20 ± 0.18%) [1]. However, the limited LE is due to the
reduced specific loading site of quercetin induced by PEG coatings [50]. Despite this,
the PEG –MNPs provide the capability to load antioxidant quercetin with low aqueous
solubility which reflects the potential of the synthesized MNPs as drug delivery carriers.
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3.3. Homogeneity and Stability of Synthesized Mesoporous MNPs
One of the essential features for successful drug delivery is stability and homogeneous
dispersion of NPs in buffer. Zeta potential was used to determine the stability of the
colloidal suspension of bare MNPs, PEG-coated MNPs and quercetin-loaded MNPs. It has
been shown that PEG-stabilized NPs exhibit longer bloodstream circulation time and higher
resistance to protein binding [44]. Due to its unique properties and its biocompatibility,
PEG is selected as the stabilizing agent in this study. The surface charge of NPs has
an important effect on the blood circulation time, the pharmacokinetics of NPs and the
zeta potential above ±30 mV indicated to be relevant for stability of NPs in aqueous
suspensions [12,51,52]. The zeta potential of MNPs (Table 1) was determined in phosphate-
buffered solution (PBS). Bare MNPs exhibited a zeta potential of (−30.6 ± 0.7) mV, while
PEG coating increased the absolute zeta potential value to (−35.1 ± 1.5) mV. Indeed, the
higher negative zeta potential value indicated that PEG-coated MNPs possessed higher
stability after PEG coating. The zeta potential of quercetin-loaded MNPs (−31.3 ± 0.8) mV
decreased slightly in comparison to PEG-coated MNPs indicating quercetin adsorption
on the PEG layer of MNPs. However, the observed change in zeta potential value did
not decrease the stability of MNPs. Moreover, the successful loading of quercetin into
PEG-coated MNPs has been confirmed also by electrophoretic measurements.
Furthermore, the hydrodynamic diameter is lower which could be attributed that PEG
coating while quercetin loading provides better colloidal stability and reduces aggregation.
The volume size distributions of all samples, i.e., bare MNPs, PEG-coated MNPs and
quercetin-loaded MNPs were unimodal. In Table 1, it can be seen that the highest polydis-
persity index was observed to be 0.54± 0.1 for the bare synthesized MNPs suspension. This
result is consistent with the results obtained from the size distribution of bare MNPs using
SEM where the size distribution of bare MNPs was broader than the size distribution of the
PEG-coated MNPs. The observed discrepancy between SEM and DLS data, particularly in
the polydispersity index (PDI), can be explained by the fact that the SEM micrographs were
taken in a dried state, whereas the DLS experiment was carried out in suspension. The PDI
results reported in Table 1 also support the conclusion that PEG coatings, even presented in
suspension, decreased the process of aggregation of bare MNPs and break down the cluster.
The average hydrodynamic diameter of both, bare and PEG-coated MNPs also supports
the above findings. In Figure 7, it is shown the volume size distributions of bare MNPs,
PEG-coated MNPs and quercetin-loaded PEG_MNPs. The PDI of PEG-coated MNPs is
lower than PDI of loaded MNPs (PDI = 0.47 ± 0.1 and 0.52 ± 0.07, respectively) indicating
narrower size distribution of the PEG-coated MNPs than quercetin-loaded MNPs (see
Figure 7). However, the cluster sizes of quercetin-loaded MNPs were within the range of
(681 ± 73) nm, which is the smallest range of all analysed MNPs. Thus, the PEG coating on
the surface of Fe3O4 decreased the size compared to the bare MNPs and indicates that the
PEG coating prevents or reduces aggregation to some extent.
Table 1. Zeta potential and hydrodynamic diameter of bare MNPs, PEG-coated MNPs and quercetin-
loaded MNPs.
Bare MNPs PEG Coated MNPs Quercetin Loaded PEG_MNPs
ζ/mV −30.6 ± 0.7 −35.1 ± 1.5 −31.3 ± 0.8
dh/nm 877 ± 105 762 ± 92 681 ± 73
PDI 0.54 ± 0.10 0.47 ± 0.10 0.52 ± 0.07
3.4. Release Study
Before we start to evaluate the quercetin-release kinetics from MNPs into PBS/EtOH
(Vol. % 50:50), we want to emphasize that the results were obtained by applying external
stationary and alternating magnetic fields. The underlying idea was to enable fine-tuned
and controlled quercetin-release kinetics, which is certainly very important in a widespread,
high-demand application of high-demand drug delivery via nanocarriers.
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The in vitro quercetin release profile from synthesized and carefully designed MNPs
was studied in duration up to 8 h with a dialysis membrane and in the presence of external
magnetic fields. The results are shown as the cumulative released mass of quercetin in
Figure 8. Within 8 h, only up o 5% of quercetin has been rele sed depending on the
experimental conditions.
A similar sustained-r leas profile of quer tin from alginate NPs at pH 7.4 has been
reporte earlier [53], where nly 10% of quercetin release was observed after 12 h, while
after 9 days, only 50% of the quercetin got released. In another study, the quercetin
release from the functionalized magnetite NPs was conducted in acidic and basic pH and
cumulative release reached 3.7% after 6 h [14]. A similar prolonged release has also been
found for quercetin release from polylactide NPs, which showed almost 60% quercetin
released after 4 days [54]. The observed slow quercetin-release kinetics offers prolonged
exposure to the drug and improves its efficiency compared with free drugs [55]. This
is considered as an advantage because the burst release of drugs leads to a significant
premature quantity of the drug that can result in toxicity [21]. For example, the quercetin
at a concentration between 0 and 200 × 10−6 mol dm−3 could decrease antioxidant activity
while quercetin at a concentration of (0.2–1) × 10−6 mol dm−3 possesses pro-oxidant
activity [56]. In addition, quercetin release was affected by oxidative degradation process
in PBS solution after continuously stirring for 6 h; this is yet another reason to employ
nanocarriers for quercetin delivery [14,57,58]. Therefore, we prepared MNPs onto which
quercetin easily adsorbs and has a prolonged stability and duration. The net result is
quercetin release for a prolonged time. A first-order release profile of quercetin from
Fe3O4-quercetin-copolymer NPs was revealed by Barreto et al. [3]. On the other hand, the
release rate of quercetin from superparamagnetic magnetite NPs coated with chitosan, PEG
and dextran was found to be of zero-order kinetics (linear with time) [41].
The assumptions in release kinetics experiments were as follows:
(i) The total amount of quercetin remained practically constant during the whole
release experiment; (ii) both the quercetin solution within the membrane interior and in
the membrane exterior were homogeneous due to the constant stirring and the fact that
quercetin solution was never saturated; (iii) the thickness of the membrane provides the
equal rate constants from the membrane interior to the membrane exterior, and vice versa;
(iv) the volume within the membrane interior Vi and the volume exterior to the membrane
Vo were constant during all performed release experiments. This is because Vi = 1 mL and
Vo = 150 mL, Vi < Vo.
As a preliminary approach in working out the data, a simple model of single ex-
ponential decay was meant to be used in which the fraction of the released drug is
Φ = 1− exp(−kt), where Φ is a fraction of drug present in the outer volume V0 (other
fractions are in the inner volume Vi. Φi, and in the membrane, Φm) [59]. The coefficient k is
related to the apparent kinetics and, as such, cannot provide information about the actual
release rate from the nanocarriers into the interior volume Vi. However, the problem with
this simple formula is the equilibrium value Φo = 1 which is achieved when the elapsed
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time is sufficiently large (t→ +∞). In our release kinetics experiments, it is invariably
between 0.04 and 0.10. Thus, the dialysis bag with its content has to be considered as
a source of drug molecules. It is not possible to know the total mass of the drug that is









= 1− e−kt (2)
where m(t) is the released mass, not a fraction of, at time t, m0 is the total released quercetin
mass from the dialysis bag after infinite time, and k is the rate coefficient of actual release
kinetics of the dialysis bag membrane. The problem is that m0 is not experimentally well
defined, i.e., it is only approximately constant across the series of experiments. Fitting
the release experimental data obtained at various magnetic fields and at three different
temperatures using this simple model (Table 2 and Figures 8 and 9) resulted as expected in
a fairly narrow interval of m0 values with average m0 = (1.48 ± 0.34) mg.
Each experiment was done in duplicate. This was fully justified to avoid averag-
ing the measurement results and use the mean values of the two fitting procedures be-






























can be used. Furthermore, it is very often m0,1≈ m0,2 which gives k ≈ 12 (k1+ k2).
It is important to emphasize that the intent of this study was not only to estimate the
time required for the complete quercetin release from nanocarriers, but also to investigate
and demonstrate how the stationary and alternating field affect the rate of quercetin release.
In our previous work [35], we have shown how the simultaneous application of stationary
and alternating field can accelerate the release of drug from aggregates of MNPs. Being
relatively unstable and dysfunctional, aggregates vigorously moved under the influence
of the alternating field which resulted in drug release enhancement. MNPs that were
additionally functionalized and stabilized by the PEG layer were used for this purpose in
the present study. Figure 8 shows the release kinetics of quercetin at the temperature of
30 ◦C in the absence of the magnetic field and under an alternating field of 10 kHz, 50 kHz
and 100 kHz at a constant stationary magnetic field B = 11 mT.
Since we used a dialysis membrane bag, the first step was to perform calibration
experiments with free quercetin following the same protocol as in experiments with MNPs
to get information about membrane permeation kinetics during the first several hours
(k = 6.617× 10−3 min−1; k = 9.637× 10−3 min−1 and k = 14.592× 10−3 min−1 at 25 ◦C, 30 ◦C
and 37 ◦C, respectively). We selected the MWCO cellulose membrane (8 kD) membrane
based on the porosity of the dialysis membrane as well as to avoid possible adverse
interactions between quercetin and the membrane materials. The cellulose membrane has
recently been used in the measurement of both, drug diffusion and drug release rates from
varied formulations, such as creams and hydrogels [7].
The rate constant of the membrane when there was non-saturated quercetin solution
in the membrane bag indicated the barrier effects of dialysis membrane and showed faster
membrane permeation kinetics at higher temperatures (k = 0.0066 min−1, 0.0096 min−1
and 0.0146 min−1 at 25 ◦C, 30 ◦C and 37 ◦C, respectively), as expected. The rate constants
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obtained in our experiments are larger than those obtained in release kinetics of doxorubicin
by Yu et al., where k = 0.019 ± 0.003 h−1 = 0.0003 min−1 [60].
With no magnetic field and at 30 ◦C, the rate constant is k = 0.0019 ± 0.0001 min−1.
At 10 kHz, 50 kHz and 100 kHz and under B =11.0 mT the rate constant values were
k = 0.0032 ± 0.0009 min−1, k = 0.0019 ± 0.0001 min−1 and k = 0.0034 ± 0.0013 min−1,
respectively. Thus, the release of the quercetin is the faster at the highest field frequency. It
is evident that the alternating magnetic field can accelerate the quercetin release at a given
stationary magnetic field.
Table 2. The experimental release kinetics under the permanent magnetic fields of 7.9 mT and 11.0 mT
and three frequencies (10 kHz, 50 kHz and 100 kHz) at temperatures 25 ◦C, 30 ◦C and 37 ◦C.
B/mT f alt.mag.f./kHz θ/◦C k/min−1 m0/mg
11.0
100
25 0.0029 ± 0.0004 0.82 ± 0.01
30 0.0034 ± 0.0013 1.38 ± 0.30
37 0.0038 ± 0.0013 1.88 ± 0.25
50
25 0.0022 ± 0.0004 1.03 ± 0.30
30 0.0019 ± 0.0001 1.41 ± 0.01
37 0.0025 ± 0.0015 3.3 ± 1.4
10
25 0.0024 ± 0.0012 1.07 ± 0.34
30 0.0032 ± 0.0009 0.97 ± 0.20
37 0.0033 ± 0.0003 1.73 ± 0.22
7.9
100
25 0.0015 ± 0.0002 1.79 ± 0.14
30 0.0032 ± 0.0003 1.15 ± 0.44
37 0.0052 ± 0.0011 1.50 ± 0.39
50
25 0.0022 ± 0.0007 1.20 ± 0.26
30 0.0022 ± 0.0008 1.86 ± 0.35
37 0.0025 ± 0.0002 1.21 ± 0.01
10
25 0.0043 ± 0.0003 1.13 ± 0.08
30 0.0021 ± 0.0006 1.30 ± 0.24
37 0.0016 ± 0.0005 1.64 ± 0.52
0 0
25 0.0022 ± 0.0004 1.03 ± 0.30
30 0.0019 ± 0.0001 1.41 ± 0.01
37 0.0025 ± 0.0015 2.25 ± 1.44
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membrane at 25 ◦C using two stationary magnetic fields and three different frequencies of alternating
magnetic field (A) 100 kHz, (B) 50 kHz and (C) 10 kHz.
Our next task was to see the effect a stationary magnetic field on release kinetics.
Figure 9 shows the dependence of quercetin-release kinetics at 25 ◦C under the alternating
field frequency of 10 kHz and stationary magnetic field of B = 7.9 mT and 11 mT (Figure 9C).
Under the stationary magnetic field of 7.9 mT, the membrane bag has released quercetin
with a rate constant k = 0.0043 ± 0.0003 min−1. When a stronger stationary field of
11 mT is applied, the release kinetics becomes slower, k = 0.0024 ± 0.0012 min−1. The
opposite effect on the release kinetics was observed at the highest 100 kHz frequency
(Figure 9A), where an increase in the rate constant with increasing stationary field by
almost 95% was observed (at B = 7.9 mT and B = 11 mT, k = 0.0015 ± 0.0002 min−1;
k = 0.0029 ± 0.0004 min−1, respectively).
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Since the opposite effects of the influence of a stationary magnetic field on the rate
constant are obtained at different frequencies of the alternating field, our next analysis fo-
cuses on the measurements of the rate constants at the same stationary field and frequency,
but at different temperatures. Comparing the constants of the apparent release rate of
quercetin at a stationary field of 7.9 mT with an increase in temperature from 25 to 37 ◦C
(k = 0.0022 ± 0.0004 min−1, k = 0.0022 ± 0.0008 min−1 and k = 0.0025 ± 0.0002 min−1
for 25 ◦C, 30 ◦C and 37 ◦C, respectively), it can be seen that the rate constant slightly
increases with increasing temperature only above 30 ◦C. The same effect was observed
under the stronger stationary field (B = 11 mT, see Table 2). At higher temperatures kinetic
energy of quercetin molecules is larger or, putting differently, their diffusivity is larger and
more quercetine is released and detected within the same time interval. If we compare
the rate constants at the same temperature (e.g., 30 ◦C), the rate constant obtained at a
stronger stationary field (B = 11 mT) and 50 KHz, is smaller (k = 0.0019 ± 0.0001 min−1)
than at a weaker field of 7.9 mT (k = 0.0022 ± 0.0008 min−1). It is obvious that when
overcoming stationary field, the thermal energy of the MNPs is large enough to increase
the movement of the MNPs and increase quercetin release. The influence of the temperature
under the constant stationary field and the frequency of the alternating field clearly shows that
the amount of quercetin released increases with increasing temperature at almost all applied
frequencies of the alternating fields except at B = 11 mT and frequencies f = 100 and 50 kHz
and at B = 7.9 mT and f = 50 kHz, which is also reflected in the magnitudes of the quercetin
release rate constants. For example, at B = 11 mT and f = 100 kHz, k = 0.0029 ± 0.0004 min−1;
k = 0.0034 ± 0.0013 min−1 and k = 0.0038 ± 0.0013 min−1 for 25 ◦C, 30 ◦C and
37 ◦C, respectively.
Thus, it was shown here that by choosing the temperature, the quercetin release rates
can cover a wide range of values. We have shown that the synthesized MNPs are suitable
nanocarriers for quercetin, especially because the required drug dose can be delivered in
a prolonged time. Since the average half-life of quercetin absorbed in the human body is
3.5 h [61], this study represents a significant improvement for flavonoid delivery, which,
when loaded into MNPs, remains stable in a prolonged period of time.
4. Conclusions
In summary, superparamagnetic magnetite nanoparticles (MNPs) were prepared by
solvothermal method and stabilized by biocompatible poly (ethylene glycol) PEG-4000
Da. The X-ray powder diffraction patterns of the synthesized bare and PEG-coated MNPs
confirmed the cubic inverse spinel structure of MNPs. The size and morphology of bare
and PEG-coated MNPs have been obtained by SEM, TEM and AFM analysis. By AFM
is showed that bare MNPs have cluster structure with a very rough surface and when
bare MNPs is coated with PEG, the roughness of the MNPs surface has been increased
by PEG coating, for almost 100%, from 5.58 ± 1.06 nm to 10.9 ± 2.1 nm, confirming the
effective coverage of the bare MNPs by PEG. A size histogram of bare mesoporous MNPs
obtained using SEM micrographs shows a broader size distribution than PEG-coated
MNPs (dave = 103.4 ± 0.7 nm and 101.0 ± 0.9 nm for bare and PEG-coated MNPs, re-
spectively), indicating that PEG decreased the magnetic interaction among the particles
and prevent their agglomeration. Nitrogen adsorption–desorption of bare MNPs and
PEG-coated MNPs confirmed their mesoporosity. The PEG molecules were successfully
coated on the surface of MNPs, as revealed by FTIR spectroscopy. The PEG-coated MNPs
spectrum showed a strong C-O-C ether stretch at 1110 and 1381 cm−1. The results of
the saturation magnetization confirmed the superparamagnetic properties of synthesized
bare and PEG-coated MNPs. The stability of MNPs improved after PEG modification,
indicated by the increase in zeta potential from (−30.6 ±0.7) mV to (−35.1 ± 1.5) mV.The
loading of quercetin into MNPs was confirmed by FTIR spectroscopy and thermogravi-
metric analysis. The UV/VIS spectra of the supernatant revealed a loading efficiency of
(20.2 ± 1.3%). The quercetin release studies in vitro followed by UV/VIS spectroscopy
have shown the prolonged quercetin-release kinetics from MNPs that could be controlled
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by using combined stationary and alternating magnetic fields. The prolonged quercetin
release, as an important characteristic for targeted drug delivery, the study of the kinetic
parameters of the quercetin release process and the increased response of quercetin release
under both the lower stationary magnetic field (7.9 mT) and the higher frequency of alter-
nating magnetic field (100 kHz) suggest that the fine tuning of the release as desired along
with synergism of physicochemical and superparamagnetic properties enables the great
potential of MNPs as a promising targeted flavonoid delivery system.
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Preparation, properties, and perspectives. Biomed. Mater. Eng. 2019, 1–46. [CrossRef]
12. Favela-Camacho, S.E.; Samaniego, J.E.; Godínez-García, A.; Avilés-Arellano, L.M.; Pérez-Robles, J.F. How to decrease the
agglomeration of magnetite nanoparticles and increase their stability using surface properties. Colloids Surf. A Physicochem. Eng.
Asp. 2019, 574, 29–35. [CrossRef]
13. Unsoy, G.; Gunduz, U.; Oprea, O.; Ficai, D.; Sonmez, M.; Radulescu, M.; Alexie, M.; Ficai, A. Magnetite: From Synthesis to
Applications. Curr. Top. Med. Chem. 2015, 15, 1622–1640. [CrossRef] [PubMed]
Antioxidants 2021, 10, 1212 19 of 20
14. Lee, X.J.; Lim, H.N.; Gowthaman, N.; Rahman, M.B.A.; Abdullah, C.A.C.; Muthoosamy, K. In-situ surface functionalization of
superparamagnetic reduced graphene oxide—Fe3O4 nanocomposite via Ganoderma lucidum extract for targeted cancer therapy
application. Appl. Surf. Sci. 2020, 512, 145738. [CrossRef]
15. Thiesen, B.; Jordan, A. Clinical applications of magnetic nanoparticles for hyperthermia. Int. J. Hyperth. 2008, 24, 467–474.
[CrossRef]
16. Jesus, P.D.C.C.D.; Pellosi, D.; Tedesco, A. Magnetic nanoparticles: Applications in biomedical processes as synergic drug-delivery
systems. Mater. Biomed. Eng. 2019, 371–396. [CrossRef]
17. Widder, K.J.; Morris, R.M.; Poore, G.A.; Howard, D.P.; Senyei, A.E. Selective targeting of magnetic albumin microspheres
containing low-dose doxorubicin: Total remission in Yoshida sarcoma-bearing rats. Eur. J. Cancer Clin. Oncol. 1983, 19, 135–139.
[CrossRef]
18. Mohanta, S.C.; Saha, A.; Devi, P.S. PEGylated Iron Oxide Nanoparticles for pH Responsive Drug Delivery Application. Mater.
Today Proc. 2018, 5, 9715–9725. [CrossRef]
19. García-Jimeno, S.; Estelrich, J. Ferrofluid based on polyethylene glycol-coated iron oxide nanoparticles: Characterization and
properties. Colloids Surfaces A Physicochem. Eng. Asp. 2013, 420, 74–81. [CrossRef]
20. Revia, R.; Zhang, M. Magnetite nanoparticles for cancer diagnosis, treatment, and treatment monitoring: Recent advances. Mater.
Today 2016, 19, 157–168. [CrossRef]
21. Wahajuddin, S.A. Superparamagnetic iron oxide nanoparticles: Magnetic nanoplatforms as drug carriers. Int. J. Nanomed. 2012, 7,
3445–3471. [CrossRef] [PubMed]
22. Assa, F.; Jafarizadeh-Malmiri, H.; Ajamein, H.; Anarjan, N.; Vaghari, H.; Sayyar, Z.; Berenjian, A. A biotechnological perspective
on the application of iron oxide nanoparticles. Nano Res. 2016, 9, 2203–2225. [CrossRef]
23. Kurczewska, J.; Cegłowski, M.; Schroeder, G. Preparation of multifunctional cascade iron oxide nanoparticles for drug delivery.
Mater. Chem. Phys. 2018, 211, 34–41. [CrossRef]
24. Tietze, R.; Zaloga, J.; Unterweger, H.; Lyer, S.; Friedrich, R.P.; Janko, C.; Pöttler, M.; Dürr, S.; Alexiou, C. Magnetic Nanoparticle-
based drug delivery for cancer therapy, Magnetic Nanoparticle-based Drug Delivery for Cancer Therapy. Biochem. Biophys. Res.
Commun. 2015, 468, 463–470. [CrossRef]
25. Akbarzadeh, A.; Samiei, M.; Davaran, S. Magnetic nanoparticles: Preparation, physical properties, and applications in
biomedicine. Nanoscale Res. Lett. 2012, 7, 144. [CrossRef]
26. Tansık, G.; Yakar, A.; Gündüz, U. Tailoring magnetic PLGA nanoparticles suitable for doxorubicin delivery. J. Nanoparticle Res.
2013, 16, 2171. [CrossRef]
27. Podaru, G.; Chikan, V. Magnetism in Nanomaterials: Heat and Force from Colloidal Magnetic Particles. In Magnetic Nanomaterials:
Applications in Catalysis and Life Sciences; Bossmann, H.S., Wang, H., Eds.; The Royal Society of Chemistry: Croydon, UK, 2017; pp.
1–24. [CrossRef]
28. Kharisov, B.I.; Dias, H.V.R.; Kharissova, O.V.; Vázquez, A.; Peña, Y.; Gómez, I. Solubilization, dispersion and stabilization of
magnetic nanoparticles in water and non-aqueous solvents: Recent trends. RSC Adv. 2014, 4, 45354–45381. [CrossRef]
29. Ali, A.; Zafar, H.; Zia, M.; ul Haq, I.; Phull, A.R.; Ali, J.S.; Hussain, A. Synthesis, characterization, applications, and challenges of
iron oxide nanoparticles. Nanotechnol. Sci. Appl. 2016, 9, 49–67. [CrossRef]
30. Knop, K.; Hoogenboom, R.; Fischer, D.; Schubert, U.S. Poly(ethylene glycol) in Drug Delivery: Pros and Cons as Well as Potential
Alternatives. Angew. Chem. Int. Ed. 2010, 49, 6288–6308. [CrossRef]
31. Rabanel, J.M.; Hildgen, P.; Banquy, X. Assessment of PEG on polymeric particles surface, a key step in drug carrier translation. J.
Control. Release 2014, 185, 71–87. [CrossRef] [PubMed]
32. Hua, X.; Yang, Q.; Dong, Z.; Zhang, J.; Zhang, W.; Wang, Q.; Tan, S.; Smyth, H.D.C. Magnetically triggered drug release from
nanoparticles and its applications in anti-tumor treatment. Drug Deliv. 2017, 24, 511–518. [CrossRef]
33. Luo, B.; Xu, S.; Luo, A.; Wang, W.-R.; Wang, S.-L.; Guo, J.; Lin, Y.; Zhao, D.; Wang, C.-C. Mesoporous Biocompatible and
Acid-Degradable Magnetic Colloidal Nanocrystal Clusters with Sustainable Stability and High Hydrophobic Drug Loading
Capacity. ACS Nano 2011, 5, 1428–1435. [CrossRef]
34. Luo, B.; Xu, S.; Ma, W.-F.; Wang, W.-R.; Wang, S.-L.; Guo, J.; Yang, W.-L.; Hu, J.-H.; Wang, C.-C. Fabrication of magnetite hollow
porous nanocrystal shells as a drug carrier for paclitaxel. J. Mater. Chem. 2010, 20, 7107–7113. [CrossRef]
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